DYNのニュース
Dyne Therapeutics PT Raised to $20 at Chardan Capital Markets 2023/03/03 12:05:02 Investing.com
https://www.investing.com/news/pro/dyne-therapeutics-pt-raised-to-20-at-chardan-capital-markets-432SI-3021564
Dyne Therapeutics GAAP EPS of -$0.74 beats by $0.11 2023/03/02 13:45:51 Seeking Alpha
Dyne Therapeutics press release (DYN): Q4 GAAP EPS of -$0.74 beats by $0.11.Cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2022, which…
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights 2023/03/02 12:30:00 GlobeNewswire
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD -
Investing in Dyne Therapeutics Inc. (DYN) might be a great opportunity, but the stock is a bit overvalued 2023/02/16 16:24:00 US Post News
Dyne Therapeutics Inc. (NASDAQ:DYN) marked $13.68 per share on Wednesday, up from a previous closing price of $13.24. While Dyne Therapeutics Inc. has overperformed by 3.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN rose by 109.82%, with highs and lows ranging from $15.63 to […]
Diving Into Dyne Therapeutics (NASDAQ:DYN) 2023/01/19 22:01:15 Seeking Alpha
Dyne Therapeutics, Inc. has enjoyed a recent bounce from good news from a rival, more than tripling in price. Click here to see our take on DYN stock.
Dyne Therapeutics Inc. (DYN) can excel with these strategies 2022/11/25 16:32:00 US Post News
A share of Dyne Therapeutics Inc. (NASDAQ:DYN) closed at $10.50 per share on Wednesday, up from $10.30 day before. While Dyne Therapeutics Inc. has overperformed by 1.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN fell by -29.86%, with highs and lows ranging from $15.90 […]
Dyne Therapeutics PT Raised to $16 at Raymond James 2022/11/03 18:14:01 Investing.com
https://www.investing.com/news/pro/dyne-therapeutics-pt-raised-to-16-at-raymond-james-432SI-2931669
Dyne Therapeutics GAAP EPS of -$0.80 beats by $0.12 (NASDAQ:DYN) 2022/11/03 13:23:00 Seeking Alpha
Dyne Therapeutics press release (DYN): Q3 GAAP EPS of -$0.80 beats by $0.12.Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2022, which…
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/03 11:30:00 GlobeNewswire
- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 -
Dyne Therapeutics to Present at Investor Conferences in November 2022/11/02 11:30:00 GlobeNewswire
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November:
Dyne Therapeutics GAAP EPS of -$1.00 misses by $0.01 (NASDAQ:DYN) 2022/03/10 13:42:32 Seeking Alpha
Dyne Therapeutics press release (DYN): Q4 GAAP EPS of -$1.00 misses by $0.01.Cash, cash equivalents and marketable securities were $376.6 million as of December 31, 2021.
NeuroMetrix, Mainz lead healthcare gainers; Dyne, Allarity among losers 2022/01/18 15:09:09 Seeking Alpha
NeuroMetrix (NURO) +39%. Mainz Biomed MYNZ +26%. Dyne Therapeutics DYN -17%. Allarity Therapeutics (ALLR) -15%.
Dyne Therapeutics Inc Shares Approach 52-Week Low - Market Mover 2022/01/09 01:49:39 Kwhen Finance
Dyne Therapeutics Inc (DYN) shares closed today at 0.6% above its 52 week low of $10.81, giving the company a market cap of $560M. The stock is currently down 8.5% year-to-date, down 53.1% over the past 12 months, and down 54.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 38.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 254.4% The company's stock price performance over the past 12 months lags the peer average by -500.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) Financial Survey 2021/12/20 08:20:42 ETF Daily News
Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility & Risk Edesa Biotech has a beta of 0.59, suggesting that its share price [] The post Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) Financial Survey appeared first on ETF Daily News .